Hercules Adjuvant Universal Delivery System is a commercial stage modified Chitosan adjuvant that is clinically proven to enhance immune response to multiple antigens.
Hercules promotes secretory immunoglobulin A (IgA) on mucous membranes, preventing pathogen invasion, even in inactivated vaccines, a crucial immune response that is traditionally only available through live vaccine formulations.
Pacific GeneTech holds the global, exclusive rights to Hercules and is the delivery system for all vaccines in development based on the Aegis system. Hercules can also be used for other vaccines and is available for partnering opportunities.
The Hercules Adjuvant System is already commercialised in South East Asia in a novel oral H5N1 vaccine for poultry and we are exploring additional commercial opportunities regionally and globally.